Sequoia Fund May Reopen to New Investors After Valeant Dive

  • `We've had a number of requests,' manager David Poppe says
  • Drugmaker lost 74% last quarter as rest of portfolio rose 4.5%

Sequoia Fund, which has faltered from its big bet on drugmaker Valeant Pharmaceuticals International Inc., is considering opening to new investors for the first time in more than two years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.